RJ Wallace Jr, BA Brown, DE Griffith, WM Girard and DT Murphy
The Center for Pulmonary Infectious Disease Control, University of Texas Health Center, Tyler, Texas 75710, USA.

Intermediate results of the first 50 patients treated with clarithromycin (CLARI) regimens for Mycobacterium avium-intracellulare (MAI) lung disease were evaluated. Patients were HIV negative, and pretreatment isolates were susceptible to CLARI. Patients received CLARI 500 mg twice daily, ethambutol, rifampin (RMP), or rifabutin (RBT) and initial streptomycin, and they were treated until culture- negative 1 yr. Eleven of 50 patients (22%) were dropped in the first 3 mo. Of the remaining 39 patients, 36 (92%) converted their sputa to negative, and 32 (82%) remain culture negative to date. This includes 11 of 16 (69%) with prior drug therapy and 21 of 23 (91%) with no prior therapy. One or more companion drugs were discontinued in 16 of 39 (41%) of patients because of adverse events. Isolates from six of 39 patients (15%) became CLARI-resistant. Of 23 patients who are alive and were culture-negative a mean of 12.0 mo while receiving therapy, all remain culture-negative without therapy a mean of 19.1 mo. Despite reduced CLARI serum levels in patients also receiving RMP, 10 of 13 patients (77%) receiving this regimen were successfully treated. Although not directly compared with previous regimens, the success of this regimen strongly suggests it is superior to previous non-CLARI- containing regimens.

This article has been cited by other articles:

				S. Kuroishi, Y. Nakamura, H. Hayakawa, M. Shirai, Y. Nakano, K. Yasuda, T. Suda, H. Nakamura, and K. Chida Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings Eur. Respir. J., July 1, 2008; 32(1): 147 - 152. [Abstract] [Full Text] [PDF]

				P A Jenkins, I A Campbell, J Banks, C M Gelder, R J Prescott, and A P Smith Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy Thorax, July 1, 2008; 63(7): 627 - 634. [Abstract] [Full Text] [PDF]

				J. Glassroth Pulmonary Disease Due to Nontuberculous Mycobacteria Chest, January 1, 2008; 133(1): 243 - 251. [Abstract] [Full Text] [PDF]

				D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]

				E. A. Waller, A. Roy, L. Brumble, A. Khoor, M. M. Johnson, and J. L. Garland The Expanding Spectrum of Mycobacterium avium Complex-Associated Pulmonary Disease. Chest, October 1, 2006; 130(4): 1234 - 1241. [Abstract] [Full Text] [PDF]

				M. Watanabe, N. Hasegawa, A. Ishizaka, K. Asakura, Y. Izumi, K. Eguchi, M. Kawamura, H. Horinouchi, and K. Kobayashi Early Pulmonary Resection for Mycobacterium Avium Complex Lung Disease Treated With Macrolides and Quinolones Ann. Thorac. Surg., June 1, 2006; 81(6): 2026 - 2030. [Abstract] [Full Text] [PDF]

				S. K. Field and R. L. Cowie Lung Disease Due to the More Common Nontuberculous Mycobacteria Chest, June 1, 2006; 129(6): 1653 - 1672. [Abstract] [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, S. Shepherd, J. McLarty, L. Griffith, and R. J. Wallace Jr. Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 250 - 253. [Abstract] [Full Text] [PDF]

				S. K. Field, D. Fisher, and R. L. Cowie Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection Chest, August 1, 2004; 126(2): 566 - 581. [Abstract] [Full Text] [PDF]

				S. K. Field and R. L. Cowie Treatment of Mycobacterium avium-intracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine Chest, October 1, 2003; 124(4): 1482 - 1486. [Abstract] [Full Text] [PDF]

				The Research Committee of the British Thoracic Soc Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Eur. Respir. J., March 1, 2003; 21(3): 478 - 482. [Abstract] [Full Text] [PDF]

				G. L. Woods, N. Williams-Bouyer, R. J. Wallace Jr., B. A. Brown-Elliott, F. G. Witebsky, P. S. Conville, M. Plaunt, G. Hall, P. Aralar, and C. Inderlied Multisite Reproducibility of Results Obtained by Two Broth Dilution Methods for Susceptibility Testing of Mycobacterium avium Complex J. Clin. Microbiol., February 1, 2003; 41(2): 627 - 631. [Abstract] [Full Text] [PDF]

				Y. Shiraishi, Y. Nakajima, K. Takasuna, T. Hanaoka, N. Katsuragi, and H. Konno Surgery for Mycobacterium avium complex lung disease in the clarithromycin era Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 314 - 318. [Abstract] [Full Text] [PDF]

				J.-i. Ashitani, H. Mukae, T. Hiratsuka, M. Nakazato, K. Kumamoto, and S. Matsukura Plasma and BAL Fluid Concentrations of Antimicrobial Peptides in Patients With Mycobacterium avium- intracellulare Infection Chest, April 1, 2001; 119(4): 1131 - 1137. [Abstract] [Full Text] [PDF]

				Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol Thorax, March 1, 2001; 56(3): 167 - 172. [Abstract] [Full Text]

				C. Jagannath, M. R. Emanuele, and R. L. Hunter Activities of Poloxamer CRL-1072 against Mycobacterium avium in Macrophage Culture and in Mice Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2898 - 2903. [Abstract] [Full Text]

				E. TANAKA, T. KIMOTO, K. TSUYUGUCHI, I. WATANABE, H. MATSUMOTO, A. NIIMI, K. SUZUKI, T. MURAYAMA, R. AMITANI, and F. KUZE Effect of Clarithromycin Regimen for Mycobacterium avium Complex Pulmonary Disease Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 866 - 872. [Abstract] [Full Text]

				R. J. WALLACE Jr., Y. ZHANG, B. A. BROWN, D. DAWSON, D. T. MURPHY, R. WILSON, and D. E. GRIFFITH Polyclonal Mycobacterium avium Complex Infections in Patients with Nodular Bronchiectasis Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1235 - 1244. [Abstract] [Full Text] [PDF]

				K. G. Nelson, D. E. Griffith, B. A. Brown, and R. J. Wallace Jr Results of operation in Mycobacterium avium-intracellulare lung disease Ann. Thorac. Surg., August 1, 1998; 66(2): 325 - 330. [Abstract] [Full Text] [PDF]

				Y. Shiraishi, K. Fukushima, H. Komatsu, and A. Kurashima Early pulmonary resection for localized mycobacterium avium complex disease Ann. Thorac. Surg., July 1, 1998; 66(1): 183 - 186. [Abstract] [Full Text] [PDF]

				Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 1 - 25. [Full Text]